Mayo Clinic proceedings
-
Mayo Clinic proceedings · Sep 2022
Editorial CommentEven When the Heart Stops, the Sex Differences Remain.
-
Mayo Clinic proceedings · Sep 2022
ReviewNonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers.
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the United States and worldwide. The progressive form of NAFLD, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplant. Comorbidities associated with NAFLD development and NASH include type 2 diabetes, obesity, metabolic syndrome, and dyslipidemia. ⋯ Current pharmacologic therapy for NAFLD is limited mainly to the use of vitamin E and pioglitazone, although other agents are being investigated in clinical trials. Cardiovascular and metabolic risk factors must also be assessed and managed. Here, NAFLD evaluation, diagnosis, and management are considered in the primary care setting and endocrinology clinics.